Skip to content
CompanyNewsHQ

CompanyNewsHQ

CompanyNewsHQ

  • Industry
    • Accountancy
    • Aerospace & Defense
    • Airline
    • Automotive
    • Chemicals
    • Construction
    • Energy
    • Facilities Management
    • Fashion
    • Finance and Utilities
    • Food and Drink
    • Insurance
    • Legal
    • Logistics
    • M&A News
    • Media & Entertainment
    • Medical Device
    • Parcels
    • Pharmaceutical
    • Private Equity
    • Retail
    • Technology
    • Telecoms
    • Travel
  • Companies A-Z
  • Submit A Press Release
  • Subscribe
  • Advertising
  • Market Analysis
  • Contact Us

Pharmaceutical Company News

The latest news from the pharmaceutical sector. Covering the latest breaking news, encompassing company news from leading pharmaceutical companies and related companies.

Pharmaceutical Company News 

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

November 23, 2020 Michael Crowe Pfizer

– If approved, marstacimab has potential to be a best-in-class treatment option among novel non-factor agents – NEW YORK-(BUSINESS WIRE)-

Read more
Pharmaceutical Company News 

New hope for treating inflammatory diseases of the kidney | Novartis

November 23, 2020 Michael Crowe Novartis

At age 14, Gisela Delgado felt unwell. She thought she had the flu, but when she noticed blood in her

Read more
Pharmaceutical Company News 

New hope for treating inflammatory diseases of the kidney | Novartis

November 23, 2020 Michael Crowe Novartis

At age 14, Gisela Delgado felt unwell. She thought she had the flu, but when she noticed blood in her

Read more
Pharmaceutical Company News 

Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics

November 23, 2020 Michael Crowe Amgen

THOUSAND OAKS, Calif., Nov. 23, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of

Read more
Pharmaceutical Company News 

GSK starts phase 3 study of RSV maternal candidate vaccine | GSK

November 23, 2020 Michael Crowe GlaxoSmithKline plc

Currently no vaccine is available for respiratory syncytial virus (RSV) RSV-associated lower respiratory tract illnesses (LRTIs) cause significant global morbidity

Read more
Pharmaceutical Company News 

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

November 23, 2020 Michael Crowe AstraZeneca
Read more
Pharmaceutical Company News 

European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older

November 23, 2020 Michael Crowe Sanofi

European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC

Read more
Pharmaceutical Company News 

Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization | Regeneron Pharmaceuticals Inc.

November 22, 2020 Michael Crowe Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Nov. 21, 2020 /PRNewswire/ — First treatment of any kind to have prospectively confirmed and statistically significant anti-viral

Read more
Pharmaceutical Company News 

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

November 20, 2020 Michael Crowe Pfizer

In addition to today’s submission to the FDA, the companies have already initiated rolling submissions across the globe including in

Read more
Pharmaceutical Company News 

Imfinzi approved in the US for less-frequent, fixed-dose use

November 20, 2020 Michael Crowe AstraZeneca

20 November 2020 07:00 GMT  Four-week dosing now approved in all Imfinzi indications, reducing medical visits and improving patient convenience

Read more
Pharmaceutical Company News 

Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

November 20, 2020 Michael Crowe Alexion Pharmaceuticals

– The new 100 mg/mL formulation will reduce infusion time by approximately 60%, lessening the burden on patients – –

Read more
Pharmaceutical Company News 

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

November 20, 2020 Michael Crowe Novartis

Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress

Read more
Pharmaceutical Company News 

Predictive analytics could bring medicines to patients faster | Novartis

November 19, 2020 Michael Crowe Novartis

Before leaving port, sailors rely on meteorological data – wind force, swell, air temperature – to help them predict weather

Read more
Pharmaceutical Company News 

New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases

November 19, 2020 Michael Crowe Novartis

Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or

Read more
Pharmaceutical Company News 

GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age | GSK

November 19, 2020 Michael Crowe GlaxoSmithKline plc

For media and investors only Issued: London UK; Philadelphia US; Geneva Switzerland GSK and Medicines for Malaria Venture (MMV) today

Read more
Pharmaceutical Company News 

Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

November 19, 2020 Michael Crowe Pfizer

LORBRENA treatment resulted in 72% reduction in risk of progression or death Data also show secondary endpoint of intra-cranial response

Read more
Pharmaceutical Company News 

Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine

November 19, 2020 Michael Crowe Pfizer

LORBRENA treatment resulted in 72% reduction in risk of progression or death Data also show secondary endpoint of intra-cranial response

Read more
Pharmaceutical Company News 

AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020

November 19, 2020 Michael Crowe AstraZeneca

19 November 2020 07:00 GMT  Presentations support Calquence efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled

Read more
Pharmaceutical Company News 

Nov 19,2020 | Chugai Receives the Best IR Award | News | CHUGAI PHARMACEUTICAL CO., LTD.

November 19, 2020 Michael Crowe Chugai Pharmaceutical Co

TOKYO, November 19, 2020 — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the company received the Best IR Award for

Read more
Pharmaceutical Company News 

Achieving 100% renewable electricity | Novartis

November 19, 2020 Michael Crowe Novartis

Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the

Read more
Pharmaceutical Company News 

Novartis set to achieve 100% renewable electricity in its European operations

November 19, 2020 Michael Crowe Novartis

Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to

Read more
Pharmaceutical Company News 

Novartis set to achieve 100% renewable electricity in its European operations

November 19, 2020 Michael Crowe Novartis

Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to

Read more
Pharmaceutical Company News 

STERIS Completes Acquisition of Key Surgical | STERIS plc

November 19, 2020 Michael Crowe STERIS plc

DUBLIN, IRELAND, Nov. 18, 2020 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that is

Read more
Pharmaceutical Company News 

Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness

November 18, 2020 Michael Crowe Pfizer

Actions include Pfizer’s S. COVID-19 Immunization Pilot Program, that aims to help inform vaccine deployment and delivery logistics nationally Pfizer has been preparing

Read more
Pharmaceutical Company News 

AbbVie Announces Expiration and Final Results of Registered Exchange Offers

November 18, 2020 Michael Crowe AbbVie

NORTH CHICAGO, Ill., Nov. 18, 2020 /PRNewswire/ — AbbVie Inc. (NYSE:ABBV) (“AbbVie“) announced today the expiration and final results of

Read more
Page 1 of 8312345...102030...»Last »

More Pharmaceutical Company News

  • Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
  • New hope for treating inflammatory diseases of the kidney | Novartis
  • New hope for treating inflammatory diseases of the kidney | Novartis
  • Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics
  • GSK starts phase 3 study of RSV maternal candidate vaccine | GSK
  • AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
  • European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
  • Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization | Regeneron Pharmaceuticals Inc.
  • Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
  • Imfinzi approved in the US for less-frequent, fixed-dose use
  • Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
  • Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
  • Predictive analytics could bring medicines to patients faster | Novartis
  • New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
  • GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age | GSK
  • Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
  • Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
  • AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020
  • Nov 19,2020 | Chugai Receives the Best IR Award | News | CHUGAI PHARMACEUTICAL CO., LTD.
  • Achieving 100% renewable electricity | Novartis
  • Novartis set to achieve 100% renewable electricity in its European operations
  • Novartis set to achieve 100% renewable electricity in its European operations
  • STERIS Completes Acquisition of Key Surgical | STERIS plc
  • Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness
  • AbbVie Announces Expiration and Final Results of Registered Exchange Offers

About

Company News HQ is a global business news portal. It is the leading industry news source for major companies across a number of industry verticals.

Links

  • Advertising
  • News Tracking Service
  • Submit News
  • Subscribe
  • Contact Us
Copyright © 2020 CompanyNewsHQ. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

  • Industry
    ▼
    • Accountancy
    • Aerospace & Defense
    • Airline
    • Automotive
    • Chemicals
    • Construction
    • Energy
    • Facilities Management
    • Fashion
    • Finance and Utilities
    • Food and Drink
    • Insurance
    • Legal
    • Logistics
    • M&A News
    • Media & Entertainment
    • Medical Device
    • Parcels
    • Pharmaceutical
    • Private Equity
    • Retail
    • Technology
    • Telecoms
    • Travel
  • Companies A-Z
  • Submit A Press Release
  • Subscribe
  • Advertising
  • Market Analysis
  • Contact Us